Related Experiment Video
Updated: Jan 8, 2026
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Tumor microenvironment-responsive conformational activation of apoA-I mimetic peptides for targeted cancer therapy
Mengjie Rui1, Lei Fang1, Mengfei Jia1
1School of Pharmacy, Jiangsu University, Zhenjiang, Jiangsu Province, People's Republic of China.
Abstract:
Apolipoprotein A-I (ApoA-I) mimetic peptides have garnered attention as potential anticancer agents owing to their role in cholesterol metabolism and ability to interact with the SR-BI receptor. However, their tendency to form lipid-bound structures in circulation limits their tumor-targeting therapeutic potential and raises the risk of off-target effects. In this study, we engineered a stimuli-responsive ApoA-I mimetic peptide by incorporating reactive oxygen species (ROS) -responsive amino acid derivatives into its sequence. Under normal physiological conditions, the peptide adopted a disordered conformation, minimizing nonspecific interactions. In contrast, the exposure to the tumor microenvironment, which is characterized by low pH and elevated ROS, could trigger a conformational transition to a structured α-helical state, thereby enhancing its membrane-disruptive and tumor-targeting capabilities. Molecular dynamics simulations predicted a rapid increase in α-helical content for the peptide candidate 5A under tumor-like conditions. These predictions were experimentally validated using circular dichroism spectroscopy, liposome leakage assays, and transmission electron microscopy, which demonstrated that peptide 5A effectively interacted with lipid membranes only upon activation in a tumor-like environment. In vitro cytotoxicity assays further confirmed the selective anticancer activity of peptide 5A under acidic conditions, while in vivo imaging and tumor inhibition studies in breast cancer models revealed significant tumor accumulation and a tumor growth inhibition rate of up to 71.43% at a 6 mg/kg dose. Our results demonstrated the potential of stimuli-responsive ApoA-I mimetic peptides for targeted cancer therapy, offering a promising strategy to enhance therapeutic efficacy while minimizing systemic toxicity.
Insights
Engineered a novel stimuli-responsive Apolipoprotein A-I (ApoA-I) mimetic peptide that targets tumors. This peptide activates in the tumor microenvironment, enhancing anticancer efficacy and reducing side effects.
Area of Science:
- Biochemistry and Molecular Biology
- Cancer Research
- Drug Delivery Systems
Background:
- Apolipoprotein A-I (ApoA-I) mimetic peptides show promise as anticancer agents due to their roles in cholesterol metabolism and SR-BI receptor interaction.
- Current ApoA-I mimetics face limitations in tumor targeting and can cause off-target effects due to lipid-bound structures in circulation.
Purpose of the Study:
- To engineer a stimuli-responsive ApoA-I mimetic peptide with enhanced tumor-targeting capabilities and reduced systemic toxicity.
- To investigate the peptide's conformational changes and anticancer activity in response to the tumor microenvironment.
Main Methods:
- Incorporation of reactive oxygen species (ROS)-responsive amino acid derivatives into an ApoA-I mimetic peptide sequence.
- Utilized molecular dynamics simulations, circular dichroism spectroscopy, liposome leakage assays, and transmission electron microscopy for characterization.
- Evaluated *in vitro* cytotoxicity and *in vivo* efficacy in breast cancer models, including imaging and tumor growth inhibition studies.
Main Results:
- The engineered peptide (5A) remained disordered under normal conditions but adopted a structured α-helical state in a tumor-like environment (low pH, elevated ROS).
- Peptide 5A demonstrated selective membrane interaction and anticancer activity under acidic conditions, validated by liposome leakage and cytotoxicity assays.
- *In vivo* studies showed significant tumor accumulation and up to 71.43% tumor growth inhibition in breast cancer models at a 6 mg/kg dose.
Conclusions:
- Stimuli-responsive ApoA-I mimetic peptides can be effectively engineered for targeted cancer therapy.
- The designed peptide exhibits enhanced therapeutic efficacy and minimized systemic toxicity by activating specifically within the tumor microenvironment.
- This approach offers a promising strategy for developing novel anticancer therapeutics with improved safety and effectiveness.
More Related Videos
![Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F68356.jpg&w=3840&q=50)
10:33Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
Published on: April 25, 2025
10:46A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
Published on: September 13, 2022
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:17The Tumor Microenvironment
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...